The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 196.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 6.00 (3.158%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 196.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron Pharma Raises EUR2.5 Million; Now Has Working Capital To 2020

Tue, 27th Aug 2019 11:38

(Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has raised EUR2.5 million via share subscription and open offer.

The company raised EUR1.0 million from the issue of 859,513 shares at EUR1.19 per share pursuant to an open offer. It also received EUR380,000 from subscription of 320,000 open offer shares not taken up.

Faron additionally raised EUR1.1 million from a separate share subscription of 941,840 shares at the same issue price, taking the total raised to EUR2.5 million before expenses.

The clinical stage biopharmaceutical firm now has working capital through to early in the first quarter of 2020.

The total number of Faron shares in issue after the subscription, open offer, and further subscription shares are issued will be 39.4 million.

Shareholder Timo Syrjala subscribed for 70,000 subscription shares via his wholly owned entity, Acme Investments SPF Sarl, for EUR80,000 - plus 168,198 open offer shares. Syrjala now owns 15% stake or 5.7 million shares in Faron Pharma.

Shares in Faron were down 1.3% at 111.00 pence in London on Tuesday.

More News
26 Aug 2021 14:56

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

Read more
25 Aug 2021 11:43

Faron doses first patient in Covid-19 treatment trial

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.

Read more
25 Aug 2021 11:38

IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment

IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment

Read more
19 Aug 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jun 2021 10:33

Faron Pharmaceuticals granted US patent for cancer immunotherapy drug

Faron Pharmaceuticals granted US patent for cancer immunotherapy drug

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 14:47

New research supports mode of action in Faron's 'MATINS' study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the publication of research supporting the immunotherapeutic blockade of 'Clever-1' to activate anti-tumour immune responses in advanced cancer patients on Thursday.

Read more
17 May 2021 17:49

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

Read more
17 May 2021 10:13

Faron Pharmaceuticals reports 'promising' data from drug study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced "promising" new data from its ongoing bexmarilimab 'MATINS' study on Monday, reporting combined headline data from 141 evaluable patients enrolled in the completed first part and the ongoing second part of the study.

Read more
14 May 2021 12:29

Faron Pharmaceuticals gets US rights to patent related to Traumakine

Faron Pharmaceuticals gets US rights to patent related to Traumakine

Read more
14 May 2021 11:18

Faron Pharmaceuticals signs US sublicence agreement

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has signed a sublicence agreement for the rights to United States patent US9,376,478, it announced on Friday, which currently extends to 2033.

Read more
23 Apr 2021 15:43

EXECUTIVE CHANGES: Universe Group hires CFO as new CEO also joins

EXECUTIVE CHANGES: Universe Group hires CFO as new CEO also joins

Read more
16 Apr 2021 14:54

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
25 Mar 2021 14:49

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

Read more
22 Mar 2021 11:22

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.